Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics.
Cullum RL, Lucas LM, Senfeld JI, Piazza JT, Neel LT, Whig K, Zhai L, Harris MH, Rael CC, Taylor DC, Cook LJ, Kaufmann DP, Mill CP, Jacobi MA, Smith FT, Suto M, Bostwick R, Gupta RB, David AE, Riese Ii DJ.
Cullum RL, et al. Among authors: gupta rb.
PLoS One. 2020 Dec 30;15(12):e0243901. doi: 10.1371/journal.pone.0243901. eCollection 2020.
PLoS One. 2020.
PMID: 33378376
Free PMC article.